The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials(Reuters file photo. Representative image)
The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials(Reuters file photo. Representative image)

Zydus Cadila seeks human trial approval for Covid-19 antibody cocktail

  • The company is seeking permission to conduct early-to late-stage human clinical trials from the Drugs Controller General of India
Reuters | , Bengaluru
UPDATED ON MAY 27, 2021 10:34 AM IST

India's Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild Covid-19, as the country grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic.

The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials, the drugmaker said, adding it was found to be safe and well-tolerated.

The therapy is a cocktail of two monoclonal antibodies, which mimic natural antibodies that the body generates to fight infection.

"At this juncture, there is a critical need to explore safer and more efficacious treatments to combat COVID," Zydus Cadila's managing director, Sharvil Patel, said in a stock exchange filing.

The company is seeking permission to conduct early-to late-stage human clinical trials from the Drugs Controller General of India, Zydus said.

The US Food and Drug Administration has given emergency use authorisations to similar treatments developed by Vir Biotechnology and GlaxoSmithKline as well as ones made by Regeneron Pharmaceuticals and Eli Lilly.

Regeneron and Roche's antibody cocktail has also received emergency use approval in India, and will be distributed by drugmaker Cipla. The first batch of the cocktail became available in the country earlier this week.

India's total coronavirus infections crossed 27 million on Wednesday, with 208,921 new cases being recorded over the prior 24 hours, while daily deaths from Covid-19 rose by 4,157.

SHARE THIS ARTICLE ON
Close
SHARE
Story Saved
OPEN APP